To determine the relationship of the multiple sites of oestrogen receptor a (ERa) phosphorylation to clinical outcome after tamoxifen therapy, sections from tissue microarrays representing over 300 ERC breast cancers from patients who were treated with surgeryCradiation and then tamoxifen were used for immunohistochemical determination of total ERa, p-S104/106-ERa, p-S118-ERa, p-S167-ERa, p-S282-ERa, p-S294-ERa, p-T311-ERa and p-S559-ERa. Relationships of phosphorylated ERa to overall and relapse-free survival (RFS; breast cancer death or recurrence) were tested using single (univariate) and multiple (multivariate) predictor statistical models. Large tumour size, node positivity, high grade, progesterone receptor (PR) negative status and low levels of p-S282-ERa were significantly associated with reduced overall survival (OS). Along with tumour size and node status, a novel phosphorylation score (P 7 score R3), taking into account all seven p-ERa sites, was significantly associated with reduced OS in univariate and multivariate analyses (hazard ratio (HR)Z2.24, 95% confidence interval (CI) 1.15-4.34, nZ335; PZ0.018). Along with tumour size, node status, grade and PR status, a high P 7 score (R3) was significantly associated with reduced RFS in univariate and multivariate analyses (HRZ1.71, 95% CI 1.03-2.86, nZ332; PZ0.039). Since ERa is the site at which integration of diverse signals occurs to regulate breast cancer growth and survival, the ERa phosphorylation score may be a surrogate marker of the balance between oestrogen-dependent and crosstalk-dependent receptor activity, and is potentially a prognostic marker of clinical outcome in a tamoxifen-treated population of patients.
Introduction
Oestrogen receptor (ERa) status of breast tumours is an imperfect marker of endocrine therapy response (Osborne 1998a,b) , and there is a need for more precise biomarkers of treatment response.
ERa is regulated by post-translational modifications such as phosphorylation. Phosphorylation of ERa at serine (S), threonine (T) and tyrosine (Y) residues has been described previously (Lannigan 2003 , Weigel & Moore 2007a . In laboratory models, ERa ligand independence and resistance to tamoxifen antagonism can occur in part due to ERa phosphorylation by kinases activated by growth factor receptor overexpression (Schiff et al. 2004 ). However, little is known of the relevance in vivo of phosphorylated ERa in breast cancer.
We were the first to show that detection of phosphorylation at serine 118 (p-S118) on ERa in breast tumours is a feature of an intact oestrogendependent signalling pathway in vivo, and is associated with a better clinical outcome in patients treated with tamoxifen (Murphy et al. 2004a,b) . Others have found similar results for phosphorylation at serine 167 (p-S167) on ERa (Yamashita et al. 2005 , Jiang et al. 2007 . Phosphorylation at these two sites in human breast tumours is generally associated with less aggressive tumour characteristics, suggestive of an intact oestrogen-responsive pathway. Furthermore, there is no difference in expression of p-S118-ERa and/or p-S167-ERa in ERC breast tumours that are HER 2-positive versus those that are HER 2-negative (Weitsman et al. 2006 , Jiang et al. 2007 ). These observations are in contrast to predictions from laboratory models, suggesting that these two sites of phosphorylation are associated with tamoxifen resistance (Campbell et al. 2001 , Jordan 2004 .
However, ERa can be phosphorylated at multiple sites (Lannigan 2003) , and additional novel sites were recently identified (Al-Dhaheri & Rowan 2006 , Williams et al. 2007 . Previously, we validated several phospho-specific antibodies for immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) breast tissue microarray (TMA) sections ). We now report that ERa phosphorylation sites are differentially associated with clinical outcome in a tamoxifen-treated population of patients.
Methods

Tissue microarrays
All primary invasive breast cancers used in this study were obtained from the Manitoba Breast Tumour Bank (MBTB, CancerCare Manitoba and University of Manitoba, www.umanitoba.ca/institutes/manitoba_ institute_cell_biology/MBTB/Index4.htm; Watson et al. 1996 . MBTB embraces the policies and operating protocols of the Canadian Tumour Repository Network (www.CTRNet.ca), and operates with approval from the Research Ethics Board of the Faculty of Medicine, University of Manitoba.
The cases used in this study were selected from over 5000 cases accrued prospectively to the MBTB over the period 1988 to the present. All biospecimens represent tumour tissues submitted through standardized clinical protocols from several hospitals to a provincial steroid receptor laboratory attached to the MBTB collection. The majority of biospecimens originated from two tertiary care centres, but the site of origin was not a factor in subsequent case selection for this study. In this period, all tissues originated from surgical resections at all centres. All tissues were initially submitted as frozen tissue, and then a portion was converted into FFPE blocks. The composition and histopathology of all biospecimens in the MBTB are routinely assessed by a standardized protocol, and entered into a computerized database to enable selection based on tissue composition and clinicalpathological parameters . Cases for this study were therefore able to be selected using inclusion criteria of ER positivity (ligandbinding assays (LBA) O3 fmol/mg protein) and known treatment (surgery, with or without radiation), which included adjuvant tamoxifen therapy, and invasive ductal or lobular histology. Potential cases were re-reviewed on haematoxylin and eosin sections by pathologists (C P and P H W) to confirm block composition and sufficient material in paraffin blocks to select areas for TMA coring. Duplicate 0.6 mm cores for each case were arrayed. By virtue of the nature of the biospecimens accrued to the MBTB, the regions cored for TMA typically corresponded to central tumour regions. Tissue collection and selection of samples for constructing TMAs have been reported before , Barnes et al. 2008 .
Overall, 450 cases were represented on the original TMAs, which were constructed prior to this study. However, due to exhaustion of tumour cores from previous use of the TMAs or incomplete data for some cases, the tumour numbers (n) analysed for some markers were !450 (as indicated in the Results section).
Clinical-pathological characteristics of the final study cohort were as follows: PR-positive (O20 fmol/mg protein), 62% (261/421); PR-negative, 38% (160/421); low-grade, 28% (118/420); intermediate-grade, 62% (260/420); high-grade, 10% (42/420); tumour size !2.5 cm, 56% (237/422); tumour size O2.5 cm, 44% (185/422); age !50 years, 7% (31/420); age O50 years, 93% (389/420); node-negative, 53% (219/415); node-positive, 47% (196/415). The median follow-up was 99 months (range 9-217 months).
Antibodies
The antibodies used for IHC were validated previously (Al-Dhaheri & Rowan 2006 ): p-S104/106-ERa, p-S282-ERa, p-S294-ERa, p-T311-ERa and p-S559-ERa were rabbit polyclonal affinitypurified antibodies (1 mg/ml, custom made by Bethyl Laboratories, Montgomery, TX, USA); p-S118-ERa (6J4, Cell Signaling, Danvers, MA, USA), p-S167-ERa (Abcam, Cambridge, MA, USA) and ERa (NCL-ER, clone 6F11, Novocastra Laboratories, Newcastle, UK) antibodies were used as previously described (Murphy et al. 2004b ). Immunohistochemistry IHC for TMAs was performed as described previously . Serial sections (5 mm) were stained with anti-ERa, anti-p-S104/106-ERa, anti-p-S118-ERa, anti-p-S167-ERa, anti-p-S282-ERa, anti-p-S294-ERa, anti-p-T311-ERa and anti-p-S559-ERa as previously described ). Briefly, sections were submitted to antigen retrieval (CC1, Ventana Medical Systems, Tucson, AZ, USA) using an autoimmunostainer (Discovery Staining Module, Ventana Medical Systems).
Quantification and cut-off selection
Slides were scored using standard light microscopy. IHC scores derive from assessment of both staining intensity (scale 0-3) and percentage of positive cells (0-100%). These two scores were multiplied to generate an IHC or H score of 0-300. Only nuclear staining was evaluated and scored. TMAs were evaluated independently by up to three investigators (G P S, C P and P H W). Where discordance was found, cases were re-evaluated to reach consensus. Since no relevant clinical cut-off points are presently reported for any phosphorylated ERa sites, positivity reported in this study was solely based on IHC scores greater than the 25th percentile ).
Relapse-free survival (RFS) was defined as the time from initial surgery to the date of clinically documented local or distant disease recurrence or death attributed to breast cancer (censors were other death). Overall survival (OS) was defined as the time from initial surgery to the date of death attributable to breast cancer (censors were other death).
Statistical methodology
Statistical analyses of survival were performed using SAS (Cary, NC, USA) version 9.1 procedure PHREG based on the modelling proposed by Cox (1972) for proportional hazard (PH) analysis. Compliance to the PH assumption was tested using the method of Lin et al. (1993) . Each model was tested and complied with the assumption of PH. Analyses were performed with single predictors and in a multivariant model with backward selection at PZ0.05 critical value. Probabilities associated with single predictors were corrected for multiple comparisons with Bonferroni's correction: p 0 Z1K(1Kp) k , where p is the probability and k is the number of comparisons.
Results
Previously, we had validated antibodies for several known and novel phosphorylated sites on ERa for IHC of TMA sections of FFPE primary breast cancer cases stored in MBTB ). ERa-positive status was confirmed by IHC as previously described ), and only tumours positive for ERa using clinically derived cut points for both LBA (O3 fmol/mg protein) and IHC (O0 H score) were included in the analysis of the relationship of multiple phospho-ERa epitopes with clinical outcome.
Single predictor (univariate) analysis is shown in Tables 1 and 2 for OS or RFS respectively. Since 13 predictors are present, both probability and Bonferronicorrected probabilities are presented for the single predictor models. Large tumour size, node positivity, high grade and PR-negative status ( Fig. 1A and B ) were all significantly associated with reduced OS and reduced RFS. These are previously identified predictors of clinical outcome and provide evidence that our study cohort is comparable to others published, despite a bias for larger tumour size due to the nature of the MBTB collection (Watson et al. 1996 , Barnes et al. 2008 and selection for ERC status. The current data confirm our earlier findings using a smaller cohort (Murphy et al. 2004a,b ) that p-S118-ERa detection is associated with significantly longer RFS (hazard ratio (HR)Z0.69, PZ0.028, nZ370) but not OS in patients treated with tamoxifen (HRZ0.74, PZ0.14, nZ370; Fig. 1A and B ). It should be noted that 51 of the cases present in our earlier study (Murphy et al. 2004a) were present on the TMAs used in the current study.
Our results show that high levels of phosphorylation at the previously unstudied site p-S282-ERa (O25% H score) are significantly associated with both longer RFS (HRZ0.61, PZ0.0039, nZ409; Fig. 1B ) and OS (HRZ0.62, PZ0.015, nZ409; Fig. 1A ) on tamoxifen. These data again support the idea that detection of p-ERa in primary breast tumours is a marker for a functional oestrogen-dependent ERa signalling pathway, and thus associated with a better tamoxifen response because these tumours are more dependent on ERa signalling for growth.
In contrast, higher phosphorylation levels at T311-ERa (O25% H score) are significantly associated with shorter RFS (HRZ1.57, PZ0.03, nZ409; Fig. 1B ) and borderline significant shorter OS (HRZ1.67, PZ0.051, nZ409; Fig. 1A ) on tamoxifen. In our hands, T311-ERa is the first phosphorylation site that is associated with a poor clinical outcome on tamoxifen. As well, it was noted that, although not significant, the HR for higher p-S559-ERa levels for OS was 1.23 and for RFS was 1.11. This outcome pattern resembles that for p-T311-ERa. These data provide further support for the idea that detection of p-ERa in primary breast tumours is a biomarker for a functional oestrogen-dependent ERa signalling pathway that can further discriminate tamoxifen response.
These results, together with our previous data ) and those of others (Jiang et al. 2007 , Yamashita et al. 2008 supporting the presence of multiple phosphorylated forms of ERa in any one ERC tumour biopsy, suggested to us that a phosphorylation code for ERa may exist, analogous to the 'histone code' that provides a measure of functionality of the protein over and above measurement of the total protein. Since multiple pathways can impact directly or indirectly on ERa to affect activity (e.g. liganddependent versus ligand-independent; agonist versus antagonist activity of tamoxifen), it is possible that a measure of the balance between 'good' and 'bad' phospho-epitopes on ERa might provide a more precise predictor of outcome to tamoxifen and possibly other endocrine therapies.
To address this hypothesis, a phospho-epitope ERa score was developed to reflect the functional balance with respect to clinical outcome of all sites measured. Scores were dichotomized using the 25th percentile IHC score for each epitope as a cut point for positive (O25th percentile value of 1) or negative. In some cases (e.g. p-S104/6-ERa, p-S118-ERa, p-S167-ERa and p-S294-ERa), the actual 25% IHC score was 0. Since in our analysis above, p-S104/6-ERa, p-S118-ERa, p-S167-ERa, p-S282-ERa and p-S294-ERa are associated with an HR !1, they were considered as 'good' factors and given a negative value (K1). Since p-T311-ERa and p-S559-ERa are associated with an HR above 1, they are considered as 'bad' factors and given a positive value (C1).
The sum of individual scores and a constant value (vZnumber of epitopes testedK2) was calculated to determine the P 7 -ERa score with the expectation that low P 7 -ERa scores would indicate better outcomes. Endocrine-Related Cancer (2010) 17 589-597 www.endocrinology-journals.org For example, a tumour positive for pS104/6-ERa, p-S118-ERa, p-S167-ERa, p-S282-ERa and p-S294-ERa, and positive for p-T311-ERa and p-S559-ERa would receive a P 7 -ERa score of 5K1K1K1K1K 1C1C1Z2; a tumour positive for p-S118-ERa and p-T311-ERa and negative for all the other sites would receive a score Z5K1C1Z5; and a tumour positive for pS104/6-ERa, p-S118-ERa, p-S167-ERa, p-S282-ERa and p-S294-ERa would receive a score Z5K1K1K1K1K1Z0.
Several cases were missing data for p-S104/6-ERa. To maximize the data set, i.e. to increase the number of cases included in the analysis, these cases were included if data from the other sites were available. However, for these cases, the constant value used was 4 instead of 5.
Using this approach, tumour phosphorylation scores of 3 or greater identified a population of patients with a significantly worse outcome on tamoxifen than those with scores below 3 ( Fig. 2A for OS and Fig. 2B for RFS). In single predictor analysis, the HR was 2.78 for OS (PZ0.0022, nZ340; Table 1 ) and 2.23 for RFS (PZ0.0012, nZ340; Table 2 ).
When multivariate analysis was undertaken, size and the phosphorylation score remained significant for OS (Table 3) , while size, grade, PR status and phosphorylation score remained significant for RFS (Table 4) . Figure 2 (A) Kaplan-Meier estimates of overall survival from breast cancer-specific death with respect to phosphorylation scoreZP 7 score (high R3). (B) Kaplan-Meier estimates of relapse-free survival from breast cancer recurrence or breast cancer-specific death with respect to P 7 score (high R3). P value represents the significance of a simple survival analysis without the proportional hazard assumption that was applied in the analyses presented in Tables 1 and 2 . In addition, a multipredictor (multivariate) analysis with backward selection was undertaken. The best predictors for OS were size, node status and phosphorylation score (Table 3 ). The HR for P 7 -ERa score was 2.24 (PZ0.018, nZ335) for OS on tamoxifen. For RFS (Table 4) , the best predictors were size, node status, grade, PR status and phosphorylation score. The HR for P 7 -ERa score was 1.71 (PZ0.039, nZ332). With the exception of grade predicting RFS, all significant associations in the multivariant analysis were also significantly considered singly with Bonferroni's correction.
Discussion
Modulation of nuclear receptor phosphorylation is known to significantly affect receptor function (Weigel & Moore 2007a,b) . Importantly, phosphorylation was suggested to affect the responsiveness of steroid receptors such as ER to SERMs such as tamoxifen (Schiff et al. 2005 , Cui et al. 2006 ). Alteration of cell-signalling pathways occurs during breast tumourigenesis and breast cancer progression, and involves modulation of kinase and phosphatase activities. This knowledge has led to the suggestion that changes in cell signalling that lead to altered ER phosphorylation may underlie, in part, the development of altered sensitivity to ligands and/or the development of resistance to endocrine therapies.
Recently, antibodies to phospho-specific epitopes on ERa became available and were deployed for breast tumour analysis. Detection of p-S118-ERa and/or p-S167-ERa and assessment of their relationship to histopathological parameters and clinical outcome to endocrine therapies (Gee et al. 2005 , Bergqvist et al. 2006 , Sarwar et al. 2006 , Jiang et al. 2007 , Yamashita et al. 2008 suggested that phosphorylation, at least at these two sites, predicted for better tamoxifen responsiveness. Presumably, this was because these tumours were more dependent on E2/ERa for growth (Murphy et al. 2004a,b) . However, in contrast to results for p-S118-ERa and/or p-S167-ERa, it was reported that detection of p-S305-ERa in breast tumours from pre-menopausal women receiving tamoxifen for 2 years was associated with no benefit (Holm et al. 2008) . Furthermore, experimental studies supported a role for p-S305-ERa in tamoxifen resistance (Michalides et al. 2004 , Zwart et al. 2007 ), suggesting that not all types of p-ERa necessarily predict good outcome in patients treated with endocrine therapies. However, we were unable to examine p-S305-ERa in our study using the antibodies available to us.
When considering possible mechanisms of action, it is interesting that the phospho-epitopes predicting for good outcome are clustered in the N-terminus of ERa. In contrast, those that predict poor outcome, i.e. p-S305-ERa and p-T311-ERa, are clustered towards the C-terminus, in the hinge region overlapping the N-terminus of the ligand-binding domain. Yamashita et al. (2008) previously suggested that differential levels of p-S118-ERa and p-S167-ERa together provide a significant marker of outcome in patients treated either with no systemic therapy, endocrine therapy or with endocrine therapy plus chemotherapy. The results presented here, along with those previously published ), extend this approach significantly to measure seven different p-ERa isoforms in over 300 ERC tumours. Results of this current larger study are generally consistent with our previous results using smaller cohorts (Murphy et al. 2004a ).
However, three additional significant and novel observations have now been made. First, high levels of the novel p-S282-ERa predicted for better outcome (RFS and OS) in a tamoxifen-treated population of patients. Second, detection of high levels of p-T311-ERa predicted a poorer outcome in a tamoxifen-treated population of patients. Third, closer examination of HRs for individual phosphorylation sites measured in this study suggested that two groups of phospho-epitopes exist: one associated with a better outcome and the other associated with a poor outcome in a tamoxifen-treated population of patients, leading us to hypothesize an ERa phosphorylation code.
We suggest that this phosphorylation code may more precisely reflect the functional status of ERa-regulated events in tumours and, therefore, may more precisely predict prognosis. Our results suggest that a low phospho-score (reflecting the balance of good over bad sites) is a statistically significant independent predictor of better OS and RFS in a tamoxifen-treated population of patients.
In laboratory models, in addition to oestrogen, several crosstalk signal transduction pathways can affect the phosphorylation state of ERa. Furthermore, each phospho-site and different pathways that may regulate it directly, or through crosstalk, are likely to be dynamic and show differential kinetics. Since ERa is pivotal in breast cancer biology, we suggest that ERa is the site at which integration of diverse signals occurs to regulate breast cancer cell growth and survival.
Since high p-S118-ERa in breast tumours was also reported to predict a better response to aromatase inhibitors (Generali et al. 2009 ), we speculate that our phosphorylation score may also predict prognosis Endocrine-Related Cancer (2010) 17 589-597 www.endocrinology-journals.org and/or treatment response to aromatase inhibitors. However, this remains to be determined, preferably using tissue samples from randomized clinical trials of aromatase inhibitors (Goss et al. 2003) . It is tempting to speculate that, since many of the same signal transduction pathways can affect phosphorylation of ERa coregulators (Wu et al. 2005) , combining the ERa phosphorylation score with that of key coregulators in breast cancer would improve prognosis and/or treatment prediction even more. However, because all patients in the cohort studied were treated with tamoxifen, our study does not differentiate between the prognostic and/or predictive significance of the P 7 -ERa score. This would require analysis of the P 7 -ERa score in a population of patients treated by surgery alone. Therefore, further studies are required to address this issue.
The current drive to provide more precise ways to inform clinical decision making with respect to personalized treatment strategies is highlighted by the TAILORx breast cancer clinical trial (http://www. cancer.gov/clinicaltrials/digestpage/TAILORx). This trial is to test the usefulness of a gene expression profile (Oncotype Dx) score to predict outcome of patients receiving endocrine therapy with and without added chemotherapy.
The same paradigm could be proposed for the ERa phosphorylation score. The ERa protein is the 'workhorse' and pivotal to the biology of ERC breast cancer. Therefore, in women with early-stage ERC breast cancer, where it is uncertain whether the patient will benefit from the addition of chemotherapy and radiation to standard endocrine therapy, the ERa phosphorylation score may help predict endocrine therapy response in the tumour.
